Abstract
In patients with aspirin-exacerbated respiratory disease (AERD), there is disparate regulation of prostaglandin E2 (PGE(2)) and prostaglandin D(2) (PGD(2)). Both prostanoids are synthesised by cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2). However, while the basal synthesis of PGE(2) tends to decrease, that of PGD(2) increases in patients with AERD. Furthermore, both behave differently in response to the inhibitory action of NSAIDs on COX-1: PGE(2) levels decrease while PGD(2) increases. Increased PGD(2) release correlates with nasal, bronchial, and extra-pulmonary symptoms caused by aspirin in AERD. The proposed hypothesis establishes that the answer to this paradoxical dissociation can be found in the airway epithelium. This is based on the observation that reduced COX-2 mRNA and/or protein expression is associated with reduced PGE(2) synthesis in cultured fibroblast and epithelial cells from AERD compared to patients with asthma who are aspirin-tolerant and healthy subjects. The low production of PGE(2) by the airway epithelium in AERD results in an excessive release of alarmins (TSLP, IL-33), which in turn contributes to activating group 2 innate lymphoid cells (ILC2s) and PGD(2) synthesis by mast cells and eosinophils. Aspirin, by further increasing the diminished PGE(2) regulation capacity in AERD, leads to respiratory reactions associated with the surge in PGD(2) from mast cells and eosinophils. In summary, the downregulation of COX-2 and the subsequent low production of PGE(2) by airway cells account for the apparently paradoxical increased production of PGD(2) by mast cells and eosinophils at the baseline and after aspirin provocation in patients with AERD. A better understanding of the role of the airway epithelium would contribute to elucidating the mechanism of AERD.